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 INTEREST OF THE AMICUS CURIAE 1 
Genformatic LLC is a company based in Austin, 
Texas, engaged in the business of genome sequencing 
and analysis.  All genome sequencing currently prac-
ticed involves isolating, purifying, and fragmenting 
DNA into varying lengths of nucleotide sequences.  
Thus, whether and to what extent third parties hold 
intellectual property rights to portions of those            
nucleotide sequences affects or impairs the ability         
of scientists, clinicians, and innovators to practice       
genome analysis and improve the technology of DNA 
sequencing.  Patents on DNA sequences that occur 
naturally in the genomes of organisms, including 
humans, also affect or impair the ability of compa-
nies such as Genformatic to engage in the business         
of DNA sequencing and analysis for medical, agri-
cultural, pharmacological, and consumer genomics 
purposes.  Genformatic is concerned that allowing 
patents to issue on nucleotide sequences that occur 
naturally in human DNA not only violates this 
Court’s traditional prohibition against patenting 
natural phenomena but also hinders the advance-
ment of science and technology in this vital area. 
  
                                                 
1 Pursuant to Supreme Court Rule 37.6, counsel for amicus 
Genformatic represents that none of the parties or their counsel 
authored this brief in whole or in part and that no person             
or entity other than amicus or its counsel made a monetary        
contribution to its preparation or submission.  Petitioners            
have lodged a blanket consent to the filing of amicus briefs, and 
written consent by respondents to the filing of this brief has 
been lodged with the Clerk of the Court.   
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SUMMARY OF ARGUMENT 
Sequencing of the human genome represents a 
revolutionary advancement in the life sciences and 
presents an opportunity to advance our knowledge          
of ourselves beyond the conception of even our most 
visionary thinkers a few decades ago.  Since the          
implementation of the first genome sequencing in the 
mid-1970s, and especially in the past few years, the 
speed of sequencing operations has exploded as the 
cost has plummeted.  As with other revolutionary 
technologies such as personal computers and cell 
phones, we are approaching an inflection point at 
which genome sequencing and analysis will become a 
realistic possibility for the general population.  This 
will allow health care providers to counsel and treat 
patients based not on generalized norms, but on          
individual genetic profiles.  With this knowledge, the 
practice of medicine and the development of thera-
peutic regimens will gradually depend less on trial 
and error and more on targeted analysis and treat-
ment.  Respondent Myriad has recognized the impor-
tance of whole genome sequencing (“WGS”) and has 
expressly represented that the claims in its patents 
“do not preempt or preclude” it.  Opp. 17.  Whether 
Myriad or any other holder of such patent rights 
would make this concession outside this litigation is 
less certain. 
Myriad does not dispute that its claims cover the 
exact sequences of nucleotide base pairs that occur 
naturally in human DNA.  See, e.g., U.S. Patent No. 
5,747,282 (filed May 5, 1998) (“ ’282 patent”), JA822 
(claims 1-7); U.S. Patent No. 5,837,492 (filed Nov. 17, 
1998) (“ ’492 patent”), JA1028 (claims 1-10).  But         
it contends that, because it has claimed “isolated”     
nucleotide sequences, it has invented something         
and should be allowed a patent on that section of the 
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human genome sequence.  To put Myriad’s contention 
into context, consider that the human genome con-
tains approximately 3 billion nucleotide base pairs.  
Myriad claims patent rights in sequences as short as 
15 base pairs.  JA822 (claims 5-6), 1028 (claim 5).  
With respect to one such claim, researchers observed 
that Myriad’s claimed sequences occurred approxi-
mately 340,000 times on chromosome 1 alone, and 
when extrapolated to the entire human sequence        
confirms their probable occurrence more than four       
million times in any human genome.2 
As an initial step, all genome sequencing tech-
niques currently practiced require randomly frag-
menting a DNA molecule into lengths of generally 
between 30 and about 1,000 base pairs.  Sequencing 
of these individual fragments generates correspond-
ing sequences of nucleotides, called “reads.”  It is          
inevitable that DNA molecules having one or more of 
the nucleotide sequences claimed in Myriad’s patents 
will appear in many different sequence reads pro-
duced during sequencing of any human genome. 
Nonetheless, Myriad relies heavily on Professor 
Holman’s articles to “debunk the myth” that WGS 
infringes its patents.  See Opp. 6, 16.  Analysis of         
his actual methodology and findings reveals that, far 
from “debunking the myth,” Professor Holman under-
scores the danger of allowing patents on naturally         
occurring nucleotide sequences.  In his study, he 
identified 4,270 U.S. patents that previously had 
                                                 
2 See Thomas B. Kepler et al., Metastasizing Patent Claims 
on BRCA1, 95 GENOMICS 312, 313 (May 2010) (“Kepler”), avail-
able at http://www.sciencedirect.com/science/journal/08887543/ 
95/5. 
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been labeled as “gene patents.”3  Although he has 
both a Ph.D. in molecular biology and a law degree, 
however, he examined only 12.5% of those patents “to 
make my task manageable.”  Holman, NATURE BIO-
TECHNOLOGY at 241.  Reading all the claims in this 
limited sample, he found that almost 70% of the           
patents he reviewed claimed “DNA molecules that      
correspond in sequence to at least some portion of a 
human gene.”  Id.  Mathematically extrapolating his 
findings to all 4,270 patents, his research indicates 
that there are 2,956 U.S. patents that claim a portion 
of the human genome – the code of life that occurs 
naturally in the genetic makeup of every human         
being.  Despite such an overwhelming number of         
patents, however, Professor Holman advocates reli-
ance on the “notoriously unpredictable undertaking” 
of claim construction to conclude that a court would 
ultimately find that gene sequencing did not infringe 
patents claiming overly broad sequences of DNA.  Id.   
Professor Holman’s position is consistent with 
other advocates of the patentability of naturally occur-
ring nucleotide sequences.  They insist that it is a      
better policy to allow such patents under 35 U.S.C. 
§ 101 and to police overreaching through claim             
construction, anticipation under § 102, obviousness 
under § 103, and the written-description requirement 
of § 112.  But this Court soundly rejected such an ap-
proach in Mayo Collaborative Services v. Prometheus 
Laboratories, Inc., 132 S. Ct. 1289, 1303 (2012).   
Furthermore, in its 2010 report to the Depart-
ment of Health and Human Services, the Secretary’s 
                                                 
3 Christopher M. Holman, Debunking the Myth that Whole-
Genome Sequencing Infringes Thousands of Gene Patents, 30 
NATURE BIOTECHNOLOGY 240, 241 (Mar. 2012) (“Holman”).   
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Advisory Committee on Genetics, Health, and Society 
observed that the patenting of human genes gives rise 
to great unpredictability and uncertainty, threaten-
ing a “patent thicket” that can inhibit future innova-
tion.4  This is exactly the danger the court recognized 
in Mayo.  See 132 S. Ct. at 1303.  The Court should 
not allow those engaged in genome sequencing to be 
deprived of such a “basic tool[ ]” of their “scientific 
and technological work.”  Id. at 1293 (internal quota-
tion marks omitted).   
 
ARGUMENT 
I. GENOME SEQUENCING INVOLVES ISO-
LATING, PURIFYING, AND FRAGMENT-
ING DNA MOLECULES INTO SEQUENCE 
LENGTHS THAT INEVITABLY FALL         
WITHIN THE EXPRESS LANGUAGE OF     
MYRIAD’S CLAIMS 
Genformatic believes that a description of gene 
sequencing will aid the Court in understanding the 
issues in this appeal.  A brief review will put that        
description in context. 
A. An Overview of the Genome 
DNA provides the blueprint by which organisms, 
including humans, are made.  The human genetic 
code is carried in molecules of DNA, arranged in 23 
pairs of chromosomes, contained in every cell of the 
body.  Each DNA molecule exists in the form of two 
                                                 
4 U.S. Dep’t of Health & Human Services, Report of the              
Secretary’s Advisory Committee on Genetics, Health, and Society:  
Gene Patents and Licensing Practices and Their Impact on          
Patient Access to Genetic Tests 51 (Apr. 2010) (“HHS Report”), 
available at http://oba.od.nih.gov/oba/SACGHS/reports/ 
SACGHS_patents_report_2010.pdf.   
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separate strands, bound together in a double helix.  
Each strand contains a sequence of nucleotides:            
adenine, guanine, cytosine, and thymine, “A, G, C, 
and T” respectively.  These are the only nucleotides 
in DNA, so the alphabet of heredity consists of only 
four letters.  Contiguous nucleotides on each strand 
are linked together in linear order by a series of 
phosphodiester bonds.   
Hydrogen bonds bind nucleotides on opposing 
strands together.  The bonds form selectively:  A on 
one strand always pairs with T on the other, while G 
always pairs with C on the opposite strand.  The          
order in which these nucleotides appear defines an      
individual’s genome.   
An essential part of the central dogma of molecu-
lar biology is the concept of a “gene.”  As originally 
conceived more than 50 years ago, a gene is a DNA 
sequence transcribed by cellular machinery into mes-
senger RNA, which in turn is translated into a pro-
tein or an amino acid polypeptide.  Scientists initially 
assumed that proteins performed all the work required 
for life, conducting essential enzymatic or biochemi-
cal reactions, mediating cellular interactions, precipi-
tating immune responses, and facilitating other func-
tions useful for propagation or survival.   
Frequently, there are differences in the expected 
DNA sequence between two organisms of even the 
same species.  These differences appear in such forms 
as single nucleotide polymorphisms, or sequence dele-
tions, insertions, or duplications.  These changes are 
often described as “mutations” or “sequence variants.”  
Some but not all of these DNA mutations or sequence 
variants may manifest in protein changes or altera-
tions in the amino acid sequence of a polypeptide.  
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Other DNA mutations may alter regulatory features 
of genes and result in differences in gene expression, 
in post-transcriptional modifications to RNA, or in 
post-translational changes to proteins.  Yet other           
genomic variation may impact interactions among 
genes or result in modifications to the three-
dimensional structure of DNA, as well as a growing 
catalogue of other consequences.   
Stated differently, scientists now appreciate that 
mutations may alter more than the amino acid          
sequence of a protein.  Other effects include modifica-
tions to gene transcription (DNA => RNA), RNA 
splicing, and translation (RNA => protein), and an 
increasing panoply of genomic interactions.  The       
detection of variants in an individual’s DNA sequence 
allows one to use any previously documented associa-
tion of those variants with disease susceptibility or 
drug safety or efficacy to assess an individual’s            
genomic heath risk.  That is, one may forecast an          
individual’s probability of exhibiting particular traits 
or health conditions based upon the detected sequence 
variation in that person’s genome.  Disease pre-
disposition and drug-risk assessment are among the 
primary reasons to do genetic testing in humans and 
other organisms.  
B. A Gene Is Any Sequence of Nucleotides 
That May Contribute to the Functional 
and Heritable Characteristics of an Organ-
ism 
The conception of a gene has evolved considerably 
in the past 50 years.  First articulated as the herita-
ble unit that produces a metabolic enzyme to do the 
biochemical work of the cell, the concept of a “gene” 
has now evolved to include any nucleic acid sequence 
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or any combination of nucleotide sequences that pro-
duces functional consequences for an organism.5  
Gregor Mendel, the father of genetics, conceived 
of a discrete unit conveying inherited characteristics 
or traits from parent to offspring.  Although he was 
not the first to use the term “gene,” Mendel was           
the first conceptually to distinguish the genotype (the 
allelic combination of heritable units) from phenotype 
(the traits or characteristics exhibited by an organ-
ism).6   
Years later, in 1941, Beadle and Tatum developed 
the hypothesis of one gene–one enzyme, and pro-
posed the mechanism of gene mutation after their 
experiments exposing mold to X-rays led to errors in 
metabolic activity.7  For several years, some errone-
ously interpreted their work to support the view that 
proteins themselves were the heritable, information-
containing biological molecules.  
 
                                                 
5 See Mark B. Gerstein et al., What is a gene, post-
ENCODE?  History and updated definition, 17 GENOME RES. 669 
(June 2007). available at http://genome.cshlp.org/content/17/ 
6/669.full.pdf+html. 
6 See Gregor Mendel, Versuche über Pflanzenhybriden, in            
4 Verhandlungen des naturforschenden Vereines in Brünn 3 
(1865).  For the English translation, see Gregor Mendel, Exper-
iments in Plant Hybridization (C.T. Druery & William Bateson 
trans., 1901) (1865), available in updated form at http://www. 
esp.org/foundations/genetics/classical/gm-65.pdf. 
7 See George W. Beadle & Edward L. Tatum, Genetic            
Control of Biochemical Reactions in Neurospora, 27 PROC. NAT’L 
ACAD. SCI. 499 (Nov. 1941), available at http://www.ncbi.nlm. 
nih.gov/pmc/articles/PMC1078370/pdf/pnas01634-0009.pdf. 
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Shortly thereafter, in 1944, Avery, MacLeod, and 
McCarty demonstrated that DNA contained a gene’s 
heritable information (by demonstrating that it could 
transform harmless bacteria into a lethal strain).8  
Hershey and Chase added to the evidence that DNA, 
not protein, was the heritable material with experi-
ments in 19529 by labeling DNA and protein with          
different radioactive isotopes and following the fate 
of those isotopes from parent to progeny. 
Watson and Crick completed the puzzle by eluci-
dating the structure of DNA as a double helix.10  The 
revelation that nucleotide bases on one strand paired 
with complementary bases on the other immediately 
suggested a mechanism for the replication of DNA 
and the mode of inheritance of traits from nucleic        
acid sequences.  Jacob and Monod subsequently defined 
the gene as a discrete sequence of DNA, transcribed 
by cellular machinery into messenger RNA and then 
subsequently translated into protein.11  The definition 
                                                 
8 See Oswald T. Avery et al., Studies on the Chemical           
Nature of the Substance Inducing Transformation of Pneumo-
coccal Types:  Induction of Transformation by a Desoxyribo-
nucleic Acid Fraction Isolated from Pneumococcus Type III, 79 
J. EXPERIMENTAL MED. 137 (Feb. 1944), available at http://www. 
ncbi.nlm.nih.gov/pmc/articles/PMC2135445/pdf/137.pdf. 
9 See Alfred D. Hershey & Martha Chase, Independent 
Functions of Viral Protein and Nucleic Acid in Growth of Bacte-
riophage, 36 J. GEN. PHYSIOLOGY 39 (Sept. 1952), available at 
http://jgp.rupress.org/content/36/1/39.full.pdf.  
10 See James D. Watson & Francis H. Crick, Molecular 
Structure of Nucleic Acids:  A Structure for Deoxyribose Nucleic 
Acid, 171 NATURE 737 (Apr. 1953), available at http://www.          
nature.com/nature/dna50/watsoncrick.pdf.  
11 See François Jacob & Jacques Monod, Genetic Regulatory 
Mechanisms in the Synthesis of Proteins, 3 J. MOLECULAR            
  
10
of “gene” as an encoder for instructions for protein 
synthesis became dogma in molecular biology for         
approximately 20 years. 
But genome sequencing and other technological 
innovations have revealed a far more complex and 
interconnected genomic landscape.  Scientists now 
appreciate that noncoding nucleic acid sequences       
control the expression of many coding sequences and 
perform other cellular functions.  Furthermore, these 
noncoding domains and the sequences they control 
may combine in networks of interacting elements 
that change during development.  Consequently, the 
environment or the tissue context in which genes          
operate may lead to alternate sequence elements or 
to regulatory changes and functional differences.         
Scientists no longer understand a “gene” purely as 
the coding sequence of nucleotides that provides          
instructions for the synthesis of a particular protein.  
Instead, the continually evolving notion of a gene 
now includes both coding and noncoding nucleotide 
sequence features that operate in interconnected and 
subtle ways to determine the functional attributes 
and heritable characteristics of an organism.12   
                                                                                                    
BIOLOGY 318 (June 1961), available at http://www.pasteur.fr/ip/          
resource/filecenter/document/01s-000046-03t/genetic-
regulatory.pdf.  
12 See John A. Stamatoyannopoulos, What does our genome 
encode?, 22 GENOME RES. 1602 (Sept. 2012), available at http:// 
genome.cshlp.org/content/22/9/1602.full.pdf+html; Jennifer Har-
row et al., GENCODE:  The reference human genome annotation 
for The ENCODE Project, 22 GENOME RES. 1760 (Sept. 2012), 
available at http://genome.cshlp.org/content/22/9/1760.full.pdf+ 
html.  
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C. The Basic Features of Genome Sequencing 
Genetic sequencing means determining the pre-
cise molecular arrangement of nucleotides in some or 
all of an individual’s DNA, one base pair at a time.  It 
is true that there are other, well-established genetic 
tests that do not involve sequencing.  For instance, 
fluorescent in situ hybridization (FISH) can identify 
structural mutations, but only those that are large 
enough to be observed through a microscope.  Poly-
merase chain reaction (PCR) techniques can confirm 
the existence of known mutations associated with a 
particular disorder.  But tests such as these have 
neither the utility nor the overall promise of sequenc-
ing.  For example, pathological conditions may arise 
from mutations that have not been previously well-
characterized, and a single experiment or reaction 
using these techniques targets only a few mutations.  
Researchers and clinicians must generally have a 
good idea of what they are looking for before they           
order these tests.  Because different genotypes can 
cause the same phenotype, moreover, there might 
well be a genetic basis for the trait or condition that 
the ordered test simply fails to reveal.    
By contrast, knowledge of the actual sequence of 
nucleotides gives a complete picture of the portion of 
DNA at issue or, in the case of WGS, of the entire 
genome.  Acquiring this information has been possi-
ble for less than 40 years, and has been practical           
only in the few years since advances in sequencing 
technology have dramatically accelerated the speed 
and reduced the cost of DNA sequencing.  See HHS      
Report at 49 (“Such multiplex testing can be useful 
when a condition involves multiple genetic factors or 
when one wants to simultaneously test for multiple 
conditions that have one or more potential genetic 
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causes.  In the past, when multiple genetic markers 
had to be tested, each genetic marker would be tested 
in a separate test, making testing complex, time-
consuming, and expensive.”). 
1. The Mechanism of Conventional                    
Sequencing 
In 1975, Sanger and Coulson described the method 
of genome analysis that would dominate the industry 
for the next 30 years.13  The first step involves break-
ing open the cell wall to isolate the DNA, then            
extracting and purifying the DNA from other cellular 
constituents and biochemicals that bind to the DNA 
molecule.  
Sequencing occurs in several steps.  First, the 
double helix DNA molecule to be sequenced is sepa-
rated (“denatured”) into its two component strands.  
One of these may be referred to as the “template 
strand,” and the other the “complementary strand.”  
The denatured strands are placed in a “soup” contain-
ing all four nucleotides, A, T, C, and G.  Most exist in 
their natural form  (dNTPs, where “N” denotes any of 
the four nucleotides).  But there is a comparatively 
small number that exist as dideoxynucleotides 
(ddNTPs).  Both forms will naturally seek a corre-
sponding nucleotide on the template strand, in effect 
forming a new complementary strand.  Because the 
ddNTPs lack the hydroxyl group to which additional 
nucleotide bases can attach, however, any new 
strand formation will end when a ddNTP attaches. 
                                                 
13 See Frederick Sanger & Alan R. Coulson, A rapid method 
for determining sequences in DNA by primed synthesis with 
DNA polymerase, 94 J. MOLECULAR BIOLOGY 441 (May 1975), 
available at http://www.sciencedirect.com/science/article/pii/ 
0022283675902132. 
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To start the sequencing reaction, a short comple-
mentary primer molecule is attached to one end of 
the template strand, and a DNA polymerase enzyme 
catalyzes the formation of the new strand.  The            
individual nucleotides begin to form hydrogen bonds 
with the corresponding base on the template strand, 
extending the new strand, one base at a time, in            
the 5’ to 3’ direction.  Whenever a ddNTP randomly 
attaches to the growing strand, however, the absence 
of a 3’ hydroxyl (OH) group precludes further strand 
extension.  The process terminates as to that strand, 
and the ddNTP marks the last complementary base 
added in the sequencing reaction.  The number of 
base pairs in the new chain, between the primer        
and the ddNTP, defines the length of the “read.”         
Because there are many fewer ddNTP molecules 
than “normal” nucleotides in the mixture, ddNTPs 
will terminate the newly synthesized strand random-
ly, resulting in reads of every possible length, up to 
the longest read length in the process.  Significantly, 
the ddNTPs terminating the new strand are chemi-
cally labeled, typically with a dye or fluorophore that 
facilitates detection of the specific ddNTP terminat-
ing each read.     
To determine the sequence of the newly synthe-
sized strand, the strands are separated and trans-
ferred to a gel or capillary tube in an electric field.  
The shorter reads move through the field more           
quickly than do longer reads.  As the reads of every 
length emerge, arranged from shortest to longest, 
they pass through a laser, which illuminates the dye-
labeled ddNTP, identifying the terminating nucleo-
tide.  This allows determination of the base sequence 
of the DNA.  Bioinformatic techniques stitch over-
lapping reads together, revealing the nucleotide           
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sequences of the relevant portion of DNA or, poten-
tially, of the entire genome.  
Stitching isolated reads back into a larger             
sequence requires many sequencing operations to            
ensure accuracy and completeness.  Thus, the most 
important technological advances in sequencing are 
those that have enabled an increasing number of 
parallel sequencing operations.  In the years follow-
ing publication of Sanger’s method, researchers devel-
oped capillary electrophoresis devices that dramati-
cally increased throughput.14  As this technology           
progressed, Sanger sequencing evolved from requir-
ing a lab bench full of gel slabs processing hundreds 
of base pairs in each run to a single machine with 96, 
and eventually 384, capillaries processing tens of 
thousands of base pairs in parallel.  In less than four 
decades, the amount of information that a sequenc-
ing operation can reveal has consistently increased 
as the price of sequencing has consistently fallen.    
Sanger biochemistry ultimately led to the map-
ping of a complete human genome.  In 2001, the         
Human Genome Project Consortium and Celera          
Genomics simultaneously published their separate 
reports, describing the first drafts of the human          
genome sequence.15  Having a reference genome for 
                                                 
14 See Harold Swerdlow et al., Capillary Gel Electrophoresis 
for DNA Sequencing:  Laser-induced Fluorescence Detection 
with the Sheath Flow Cuvette, 516 J. CHROMATOGR. 61 (Sept. 
1990); Tim Hunkapiller et al., Large-scale and Automated DNA 
Sequence Determination, 254 SCIENCE 59 (Oct. 1991).   
15 See J. Craig Venter et al., The Sequence of the Human 
Genome, 291 SCIENCE 1304 (Feb. 2001); International Human 
Genome Sequencing Consortium, Eric S. Lander et al., Initial 
Sequencing and Analysis of the Human Genome, 409 NATURE 
860 (Feb. 2001).     
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comparison, coupled with the advances in technology, 
has made it possible to identify sequence variants by 
comparison to the reference sequence.  Alignment 
and mapping of sequence reads to the reference            
genome has also enabled complete genome sequences 
of individuals (i.e., other than the reference genome).  
Significantly, mapping to a reference bypasses the 
more complex, expensive, and time-consuming task 
of de novo genome assembly.  The human genome 
project also spurred the development of many “next-
generation sequencing” methods, further accelerating 
the breathtaking pace of scientific discovery.16 
2. The Promise of Next-Generation           
Sequencing 
Genformatic emphasizes two points with respect 
to the evolution of gene sequencing.  First, although 
sequencing has been possible for less than 40 years, 
the advances have been remarkable.  With continu-
ing advances in next-generation techniques, the pos-
sibilities are almost endless.  To put the advances         
into context, Sanger sequencing can process only           
up to 384 samples in parallel, even with the advances 
in technology.  Next-generation sequencing includes 
cyclic-array strategies in which “hundreds of millions 
of sequencing reads can potentially be obtained in 
parallel.”  Shendure 2008 at 1136.  As capabilities 
have expanded, sequencing increasingly has become 
                                                 
16 A detailed analysis of “next generation” sequencing is far 
beyond the scope of this brief and is unnecessary for the resolu-
tion of the issue presented in this case.  For a general overview, 
see Jay Shendure & Hanlee Ji, Next-generation DNA sequencing, 
26 NATURE BIOTECHNOLOGY 1135 (Oct. 2008) (“Shendure 2008”), 
and Jay Shendure & Erez Lieberman Aiden, The expanding 
scope of DNA sequencing, 30 NATURE BIOTECHNOLOGY 1084 
(Nov. 2012) (“Shendure 2012”). 
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a basic tool of life science.  “Sequencing is emerging 
as a ubiquitous, digital ‘readout’ for the deep, com-
prehensive exploration of genetics, molecular biology 
and cellular biophysics.”  Shendure 2012 at 1092.  
Indeed, those in the industry expect it to dominate 
the entire life science field for the near future and to 
provide important new tools for clinical medicine. 
Today, sequencing has an increasingly funda-
mental role in the genetic analysis of human 
disease and model organism phenotypes as 
well as in addressing basic questions in organ-
ismic and cellular biology. . . . We predict that 
much of the agenda of biology in the coming 
decade will be driven in large part by the           
scientific opportunities afforded by next-
generation DNA sequencing technologies. 
Id. at 1084.   
As technology has advanced, accessibility has             
increased.  Newer sequencing instruments “have 
fewer infrastructure requirements.”  Shendure 2008 
at 1141.  Concomitantly, “[t]he cost of DNA sequenc-
ing has plummeted since 2005, from $1,000 per 
megabase down to a mere ten cents per megabase.”  
Shendure 2012 at 1084 (citation omitted).  “The            
reduction in the costs of DNA sequencing by several 
orders of magnitude is democratizing the extent to 
which individual investigators can pursue projects at 
a scale previously accessible only to major genome 
centers.”  Shendure 2008 at 1143. 
With the advances in technology, the decrease in 
cost, and the increase in accessibility, sequencing is 
poised to move from purely research applications              
to commercial applications as well.  It will soon be 
possible to sequence an individual’s whole genome 
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for less than $1,000.17  The practice of medicine to 
date has relied on treatment regimens (including 
pharmaceutical formulations) generalized to the en-
tire population.  This necessarily leads to much trial 
and error in selecting an effective treatment regimen, 
as well as to many adverse effects in patients for 
whom a particular treatment regimen might be 
harmful.  Armed with an individual’s entire genetic 
code, health care providers and pharmaceutical com-
panies will be able to tailor treatment and target 
conditions to an extent that has been unimaginable 
to date.18  Sequencing provides the major stimulus in 
the evolution to personalized medicine. 19   
                                                 
17 See Kevin Davies, The $1,000 Genome:  The Revolution in 
DNA Sequencing and the New Era of Personalized Medicine 
(Free Press, New York 2010).   
18 As with all technological advances, society will have 
choices to make with respect to such issues as accessibility of 
genetic information and privacy concerns.  See, e.g., Bonnie 
Rochman, The DNA Dilemma:  A Test That Could Change Your 
Life, TIME, Dec. 24, 2012, at 42.  Genformatic does not belittle 
these concerns and proactively considers them in its business 
plan.  But these concerns do not eliminate the benefits that           
sequencing can provide to individuals and to our society as a 
whole. 
19  The advances in technology have allowed sequencing to 
progress from individuals to entire populations.  Genome-wide 
association studies (“GWAS”) have generated a rapidly increas-
ing body of knowledge about genetic markers associated with a 
phenotype of interest (e.g., stroke, multiple sclerosis, or breast 
cancer).  GWAS studies are conducted by identifying thousands 
of individuals with a phenotype of interest and genotyping those 
“cases” for hundreds of thousands of genetic markers(typically 
single nucleotide polymorphisms, or “SNPs”), then comparing 
the incidence of particular genotypes in cases to the incidence of 
genotypes in a similar “control” group (which lack the pheno-
type of interest).  Statistical analysis of GWAS data allows 
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Second, although there are differences among the 
various next-generation methods, “the great variety 
of sequencing experiments is a result of distinct com-
binations of a relatively small set of core techniques.”  
Shendure 2012 at 1091, fig. 3.  The advances in next-
generation sequencing primarily involve the actual 
sequencing operations.  As with Sanger sequencing, 
however, the first step remains isolating, purifying, 
and fragmenting the DNA molecule.  Thus, next-
generation sequencing remains equally vulnerable to 
patents on naturally occurring nucleotide sequences.   
To put the numbers into context, the Sanger 
method can sequence a read of up to approximately 
1,000 base pairs.  The read lengths in next-
generation sequencing vary from less than 20 base 
pairs to several hundred.  See Shendure 2008 at 
1140, table 1; Shendure 2012 at 1187, table 2.  Only 
one sequencing instrument currently available can 
sequence reads longer than 1,000 base pairs.20  See 
                                                                                                    
identification of markers associated with the phenotype of            
interest.  For a brief overview and a searchable database, see 
http://www.genome.gov/gwastudies/.   
Note that GWAS studies do not necessarily identify causal 
mutations, but rather sequence variants linked to a trait.  This 
association allows assignment of an individual to a higher or 
lower relative-risk category for a particular phenotype depend-
ing on the presence or absence of a SNP in their genome.  The 
explosion of GWAS is illustrated by a time series depiction of 
the rapidly expanding catalogue of GWAS markers and traits.  
See http://www.ebi.ac.uk/fgpt/gwas/#timeseriestab.  As GWAS 
studies move from genotyping hundreds of thousands of SNPs 
to WGS, the rate of knowledge generation will only accelerate, 
increasing the probability of identifying causal mutations for 
disease and other traits. 
20 A higher error rate in calling individual bases tempers 
this read length advantage.  See http://www.pacificbiosciences. 
com/pdf/Poster_High_Throughput_Long_Read_PacBio_RS.pdf. 
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Shendure 2008 at 1140, table 1; Shendure 2012 at 
1187, table 2.  Comparing current read lengths to the 
3 billion base pairs in the entire human genome,           
distributed among 23 pairs of chromosomes, it is 
clear that even the most advanced sequencing tech-
nology currently available must isolate, purify, and 
fragment relatively tiny sequences of nucleotides as         
a necessary first step.  As technology continues to        
advance, read lengths should continue to increase 
and costs should continue to decrease.  Eventually, 
there will be a sequencing method that will produce 
fast, accurate sequence reads comprising tens of 
thousands of base pairs or more. 
II. ALLOWING PATENTS ON NATURALLY 
OCCURRING NUCLEOTIDE SEQUENCES 
THREATENS TO INHIBIT FUTURE INNO-
VATION 
Enforcement of patents on naturally occurring 
nucleotide sequences threatens to inhibit these            
advances. 
A. The Implications of Patent Rights in Nat-
urally Occurring Nucleotide Sequences 
The ’282 patent contains the following claims: 
5.  An isolated DNA having at least 15 nucleo-
tides of the DNA of claim 1. 
6.  An isolated DNA having at least 15 nucleo-
tides of the DNA of claim 2. 
JA822.  As their wording suggests, both of these           
are dependent claims, referencing claims 1 and 2 of 
the ’282 patent.21  Although claim 1 and claim 2          
                                                 
21 The ’282 patent covers BRCA1.  Claim 5 of the ’492 pa-
tent, covering BRCA2, is analogous to claim 5 of the ’282 patent.   
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ultimately claim the same thing – the nucleotide           
sequence of the BRCA1 gene – they do so from two 
different angles.  Claim 1 refers to the polypeptide 
synthesized by the BRCA1 gene, defining the nucleo-
tide sequence by what it makes.  Claim 2 refers to 
the sequence of the DNA itself.    
The BRCA1 sequence in Myriad’s claim 2 (which 
includes both coding and noncoding portions) is 5,914 
base pairs in length, JA822 (claim 2).  Because they 
refer back to claims 1 and 2, claims 5 and 6 cover any 
sequence “having at least 15 nucleotides” (“15mers”), 
occurring anywhere along a length of almost 6,000 
nucleotides. 
Consider that (i) the entire human genome con-
sists of approximately 3 billion nucleotide base pairs, 
(ii) there are only four nucleotides in DNA, A, T, G, 
and C, and (iii) modern sequencing methods must 
first isolate, purify, and segment DNA into reads 
that typically range from 30 to 1,000 base pairs in 
length.  Given these facts, it is mathematically inevi-
table that sequences “having at least 15 nucleotides 
of the DNA of claim 1” will occur somewhere in a           
genome consisting of a 3 billion base pair sequence of 
nucleotides.  Consequently, it seems inevitable that 
nucleotide sequences within the express language of 
these claims will be isolated in the course of sequenc-
ing any human genome. 
The actual calculations confirm this inevitability.  
A team of researchers worried that “[o]ne of these 
claims seemed to us particularly broad, so we inves-
tigated it, doing simple calculations to estimate its 
                                                                                                    
5.  An isolated DNA molecule comprising at least 15 
contiguous nucleotides of the DNA molecule of claim 1.  
JA1028. 
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reach.”  Kepler, 95 GENOMICS at 312.  They observed 
that claim 1 of the ’282 patent embodies approxi-
mately 1.6 million 15mer sequences, estimating that 
there are approximately 15 infringing sequences per 
human gene of average length.  Id. at 313.  To exper-
imentally confirm this estimation, the researchers 
focused on chromosome 1.  They empirically verified 
“over 340,000 matches of claimed 15-mers to the          
250 million base pairs of chromosome 1,” indicating 
“about 14 infringing sequences per human gene.”  Id.  
Not surprisingly, the researchers concluded that 
“[t]his claim and others like it turn out, on examina-
tion, to be surprisingly broad, and if enforced would 
have substantial implications for medical practice 
and scientific research.”  Id. at 312.   
B. The “Bright Line Prohibition” Against         
Patenting Natural Phenomena 
Even those who support gene patentability under 
§ 101 do not disagree.  On October 28, 2010, Profes-
sors Christopher M. Holman and Robert Cook-
Deegan submitted an amicus brief in this case in the 
court of appeals.  This was in the first appeal to the 
Federal Circuit, prior to this Court’s opinion in Mayo.  
With respect to claim 5 of the ’282 patent, they wrote 
that, “[i]n principle, fragment claims such as this 
provide much broader coverage than claims reciting 
full-length genes, and would appear to encompass 
conventional BRCA mutation testing that involves 
the amplification and analysis of DNA fragments as 
used in diagnostic testing.”22  The professors demon-
strated the breadth of this claim: 
                                                 
22 Brief of Amici Curiae Christopher M. Holman and Robert 
Cook-Deegan in Support of Neither Party at 20, Association for 
Molecular Pathology v. United States Patent & Trademark Office, 
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In particular, a recent study found that 80%          
of the cDNA and mRNA sequences that were 
contributed to GenBank (and hence presuma-
bly published) before the effective filing date           
of the ’282 patent contain at least one DNA 
fragment falling within the scope of Claim 5, 
and thus would apparently be encompassed by 
the claim.  [Kepler].  Follow-up studies have 
shown many “hits” of 15-mer sequences in 
GenBank sequences that had already been         
deposited more than a year before patent ap-
plication, thus implicating 35 USC 102(b). 
Holman Amicus Br. at 20-21. 
By opining that the sheer breadth of claim 5 
would ultimately cause it to fail for lack of novelty, 
they supported their broader point:  that courts 
should address patents on human genes “more surgi-
cally and appropriately . . . with other patent law 
doctrines [such as claim construction, anticipation, 
non-obviousness, and written description], or legal 
and policy solutions addressing problematic enforce-
ment practices” rather than under § 101.  Id. at 4-5, 
20-21.  But this ignores a critical issue.  Myriad 
drafted claims 5 and 6, and the USPTO granted the 
’282 patent, including those claims.  Those claims are 
currently part of an existing United States patent, 
entitled to the presumption of validity in 35 U.S.C. 
§ 282.  And, while “Myriad has only rarely enforced 
its patents in research, [it] has vigorously enforced 
its patents against commercial genetic testing, and 
has selectively enforced its patents in clinical research. 
. . . BRCA research in the United States continues 
                                                                                                    
653 F.3d 1329 (Fed. Cir. 2011) (No. 2010-1406) (filed Oct. 28, 
2010) (“Holman Amicus Br.”), 2010 WL 4853323.   
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only with Myriad’s indulgence.”  Kepler, 95 GENOMICS 
at 313.23 
                                                 
23 Myriad’s past conduct undermines trusting its continued 
indulgence. 
The fact that Myriad has allowed research to go forward 
– most of which infringes its intellectual property – is 
laudable, but tempered by distrust.  If Myriad had a 
reason to go after researchers, would it do so?  Indeed, it 
has. 
Myriad restricted BRCA testing for clinical research 
by suing OncorMed and the University of Pennsylvania.  
All testing at the time was part of research, includ-         
ing trials funded by the National Cancer Institute.         
Myriad’s definition of permissible “research” testing by 
others was quite narrow; its definition of appropriate 
testing in its own laboratory, however, was expansive, 
including clinical testing performed at a time when all 
health professional recommendations urged testing only 
in the context of research.  OncorMed agreed to test          
only in research protocols, and Penn was a testing core 
for multi-institutional trials.  It was Myriad that broke 
from professional standards to do clinical testing out-
side of research protocols in the early years.  Myriad 
thus exercised its patent exclusivity in two ways:  to estab-
lish a U.S. service monopoly and flout clinical guidelines 
in its own testing and to impose a narrow definition of 
research on others’ BRCA testing.  The Supreme Court 
may decide “Progress in Science and the useful Arts” is 
better served by clear legal limits on what can be               
patented at all, rather than leaving decisions about 
freedom to do research with patent-holders. 
Robert Cook-Deegan, Law and Science Collide Over Human 
Gene Patents, 338 SCIENCE 745, 747 (Nov. 2012) (footnotes         
omitted, emphases added), available at http://people.duke.edu/ 
~ab389/PubList/BCD%20SCience745.full.pdf. 
Myriad’s gene patents have also empowered it to construct 
and maintain a proprietary library of gene testing results.  See 
Robert Cook-Deegan et al., The Next Controversy in Genetic Test-
ing:  Clinical Data as Trade Secrets 2 (Nov. 14, 2012) (advance 
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More importantly, the Court squarely rejected 
this argument in Mayo.  “This approach . . . would 
make the ‘law of nature’ exception to § 101 patenta-
bility a dead letter.  The approach is therefore not 
consistent with prior law.”  132 S. Ct. at 1303.  The 
argument that claims 5 and 6 of the ’282 patent are 
so broad that they cannot be valid presents the flip-
side of the patent holder’s argument in Mayo.  There, 
the holder “argue[d] that, because the particular laws 
of nature that its patent claims embody are narrow 
and specific, the patents should be upheld.”  Id.  But 
the Court refused to resolve the § 101 inquiry based 
on the breadth or narrowness of the claims, observ-
ing that: 
Courts and judges are not institutionally            
well suited to making the kinds of judgments 
needed to distinguish among different laws of 
nature.  And so the cases have endorsed a 
bright-line prohibition against patenting laws 
of nature, mathematical formulas and the like, 
which serves as a somewhat more easily ad-
ministered proxy for the underlying “building-
block” concern. 
Id.  Claims 5 and 6 illustrate the wisdom of this         
approach.  Because a nucleotide sequence is a natural 
                                                                                                    
online publication; to be published at — EUR. J. HUM. GENETICS 
—) (“Myriad has access to public databases in interpreting            
mutations, but outsiders do not have access to Myriad’s data-
base.”), available at http://www.nature.com/ejhg/journal/vaop/ 
ncurrent/pdf/ejhg2012217a.pdf.  Hoarding data in this manner 
has significant implications for WGS.  “In an environment in 
which new technologies, including whole-genome and whole-
exome sequencing, are already beginning to change clinical 
practices in genetic testing, a proprietary database gives Myriad 
indefinite exclusivity independent of patent protection.”  Id. 
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phenomenon, it is not patent-eligible under § 101 – 
no matter its length.  
C. Not “Debunking the Myth,” But Proving 
the Point 
If the Court allows patents of naturally occurring 
nucleotide sequences under § 101, genome sequenc-
ers face significant practical difficulties.  Professor 
Holman, in attempting to “debunk the myth” that 
WGS infringes patents such as the patents in suit, 
underscored these difficulties.  To address the “mis-
conception” that “20% of human genes are patented,” 
he contacted the author of the article cited for that 
proposition, see Kyle Jensen & Fiona Murray, Intel-
lectual Property Landscape of the Human Genome, 
310 SCIENCE 239 (2005), and obtained a list of the 
4,270 “gene patents” cited in the article.  Holman, 30 
NATURE BIOTECHNOLOGY at 240-41.  His review of 
these patents reveals the enormity of the task:  
“Each patent contains multiple patent claims, some-
times hundreds of claims, so to make my task            
manageable I randomly selected 533 of the 4,270         
patents and reviewed all of the claims in each of          
these patents.”  Id. at 241 (emphasis added).  In         
other words, the “unmanageability” of the task led him 
actually to review only 12.5% of the cited patents.   
Nonetheless, his results were telling.  He found 
that 369/533 patents he examined – 69.2% – claimed 
“DNA molecules that correspond in sequence to at 
least some portion of a human gene,” presumably          
because these claims “explicitly mentioned” “at least 
some portion of the gene’s DNA sequence, or the 
amino acid sequence of the corresponding protein.”  
Id.  Assuming that his sample was representative, 
and multiplying the entire sample by the percentage 
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he found, his findings indicate that there are 2,856 
U.S. patents that claim patent rights to a portion of a 
naturally occurring nucleotide sequence in a human 
DNA molecule.  
Despite these overwhelming numbers, Professor 
Holman concluded that a construction of such claims 
that is broad enough to endanger gene sequencing 
would likely lead a court to declare the patent              
invalid.  Specifically, he focuses on the widespread 
use of the word “isolated” in drafting claims, id., 
claim language that Myriad has used in the claims at 
issue.  Professor Holman acknowledges that Profes-
sor Cook-Deegan “believes that any technology for 
reading a DNA sequence will necessarily involve iso-
lation and thus constitute infringement if the term 
‘isolated’ is interpreted broadly, a possibility he feels 
cannot be ruled out,” and agrees that “it is impossible 
to entirely rule out the possibility that a court would 
interpret a claim to an isolated DNA molecule in the 
extremely broad sense suggested by Cook-Deegan.”  
Id. at 242.24  Yet Professor Holman is Myriad’s pri-
mary authority for the proposition that WGS does 
not infringe its patents.  See Opp. 6, 16.   
Professor Holman does acknowledge the un-
certainty inherent in relying on claim construction         
to police overreaching patents.  He observes that       
“the interpretation of patent claims, particularly         
outside the context of patent infringement litigation, 
is a notoriously unpredictable undertaking” that is            
                                                 
24 This “possibility” would be consistent with the Manual of 
Patent Examining Procedure (rev. ed. Aug. 2012), which stipu-
lates that claims be given their “broadest reasonable interpreta-
tion.”  MPEP § 2111.  The court of appeals has endorsed broad 
interpretation in the context of claim construction.  See Phillips 
v. AWH Corp., 415 F.3d 1303, 1316 (Fed. Cir. 2005) (en banc).  
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“especially pronounced with respect to gene patents.”  
Holman, 30 NATURE BIOTECHNOLOGY at 241.  Because 
“[i]t is not uncommon for the Federal Circuit judges 
to disagree among themselves as to the proper inter-
pretation of a claim,” “some, including at times the 
Federal Trade Commission, [have] characterize[d] 
patents as mere ‘probabilistic’ property rights.”  Id.  
Nonetheless, he concludes that “the vast majority of 
these patents would almost certainly not be infringed 
by WGS, either because they are not gene patents at 
all, or because they only claim isolated DNA mole-
cules unlikely to be produced in WGS.”  Id. at 244.  
In any event, he opines that any award of damages 
for infringement “would most likely be minuscule 
considering the relative contribution of the patented 
invention to the sequencing of the entire genome.”  
Id. 
Far from “[d]ebunking the myth that [WGS]          
infringes thousands of gene patents,” Professor Hol-
man’s analysis confirms that there are almost 3,000 
U.S. patents whose claims “explicitly mention[]” “at 
least some portion of the gene’s DNA sequence, or the 
amino acid sequence of the corresponding protein.”  
Id. at 240, 241.  His reliance on the ultimate invalid-
ity of claims to police overreaching largely leaves the 
patenting of naturally occurring nucleotide sequences 
to the “notoriously unpredictable undertaking” of claim 
construction.  Id. at 241.     
Genformatic asserts that his approach improperly 
tasks courts and judges with determining the degree 
to which exclusive rights to naturally occurring             
sequences of nucleotides inhibit future innovation, a 
task to which they “are not institutionally well suit-
ed.”  Mayo, 132 S. Ct. at 1303.  The better approach 
is to confirm the “bright-line prohibition” against            
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patenting natural phenomena, thereby avoiding the 
“danger that becomes acute when a patented [compo-
sition] . . . forecloses more future invention than the 
underlying discovery could reasonably justify.”  Id. at 
1301, 1303. 
D. The Inhibition of Innovation 
A decade ago, a group of professors and research-
ers interviewed 122 directors of U.S. laboratories per-
forming DNA-based genetic tests.  They found that 
“[t]wenty-five percent of respondents reported that 
they had stopped performing a clinical genetic test 
because of a patent or license.  Fifty-three percent of 
respondents reported deciding not to develop a new 
clinical genetic test because of a patent or license.  In 
total, respondents were prevented from performing 
12 genetic tests, and all of these tests were among 
those performed by a large number of laboratories.”25  
The cause was not difficult to ascertain:  “Almost 
two-thirds of the laboratory directors in our sample 
had been contacted by a patent- or license-holder 
about the laboratory’s potential infringement of a          
patent by performance of a genetic test.”  Cho, 5 J. 
Molecular Diagnostics at 5-6 (discussion).  
We conclude that patents and licenses have a 
significant negative effect on the ability of clin-
ical laboratories to continue to perform already 
developed genetic tests, and that these effects 
have not changed substantially throughout the 
past 3 years.  Furthermore, the development of 
new genetic tests for clinical use, based on 
                                                 
25 Mildred K. Cho et al., Effect of Patents and Licenses on 
the Provision of Clinical Genetic Testing Services, 5 J. Molecular 
Diagnostics 3, 3 (Feb. 2003), available at http://www.ncbi.nlm. 
nih.gov/pmc/articles/PMC1907368/pdf/0108.pdf.   
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published data on disease-gene associations, 
and information sharing between laboratories, 
seemed to be inhibited. 
Id. at 8 (conclusion).  Notably, BRCA1/BRCA2 were 
among the genes whose patent holders had contacted 
the labs.  Id. at 5 (Effects of Patents and Licenses on 
Clinical Genetic Testing Services).   
In 2010, the Secretary’s Advisory Committee on 
Genetics, Health, and Society confirmed “that patents 
have been used to narrow or clear the market of            
existing tests, thereby limiting, rather than promot-
ing availability of testing.”  HHS Report (transmittal 
letter).  The advisory committee emphasized the dan-
ger to innovation:  “The substantial number of exist-
ing patents on genes and methods of diagnosis also 
pose a threat to the development of multiplex testing, 
parallel sequencing, and whole-genome sequencing, 
the areas of genetic testing with the greatest poten-
tial future benefits.”  Id. 
To avoid infringement proactively, sequencers of 
multiple genes or of the whole genome must identify, 
then try to license, all genes involved in the proposed 
test.  “The alternative of leaving patented genes out 
of a multiplex test or not reporting the results per-
taining to those genes undermines the very clinical 
utility of multiplex analysis.”  Id. at 50.  But identify-
ing, contacting, and reaching an agreement with the 
patent holders presents enormous difficulties.  The 
advisory committee discovered that ownership of the 
4,270 “gene patents” identified in Jensen & Murray’s 
2005 article was distributed among 1,156 different 
assignees. 
The existence of so many patents protecting 
genes, spread among various assignees, creates 
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a “patent thicket” – “a dense web of overlap-
ping intellectual property rights that a company 
must hack its way through in order to actually 
commercialize new technology.”  To hack through 
this thicket to develop a multiplex test, a              
developer would face several challenges.  The 
developer first would have to identify all the 
patents requiring licenses.  This effort would 
involve a costly search for relevant patents 
and an analysis of their claims to determine 
whether the proposed multiplex test would in-
fringe each particular claim.  Once the patents 
relevant to the test were identified, the devel-
oper would have to determine whether licenses 
were available for each patent.  The case stud-
ies revealed that such licensing information        
often is difficult to obtain.  Finally, the devel-
oper would have to separately negotiate licenses 
with each individual patent holder.   
Id. at 51 (footnote omitted).  Although Professors 
Holman and Cook-Deegan argue that more “surgical[ ]” 
doctrines such as claim construction would eventually 
cure the problem,26 Holman Amicus Br. at 5, they 
have acknowledged that, “[i]f ‘isolated’ is so expan-
sive that full-genome sequencing infringes thousands 
of individual gene claims, then a serious patent 
thicket could arise,” id. at 19-20. 
Sequencers could avoid the problem, at least          
temporarily, by proceeding with development, then        
                                                 
26 To be clear, Genformatic hopes that Professors Holman 
and Cook-Deegan are correct and indeed believes that there is          
a likelihood that all patents on naturally occurring nucleotide 
sequences in DNA would eventually be invalidated.  But allow-
ing such patents to bypass § 101 effectively sanctions the inhibi-
tion of innovation in contravention of this Court’s directives. 
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defending any infringement suits as they appear.  The 
advisory committee advised against this approach, 
however, noting that innovators who have already 
funded projects are “easier prey for patent holders.”  
HHS Report at 52.  “Choosing to proceed with a 
product involves the risk of being sued, and the            
expense of defending against suits that arise diverts 
funds that could otherwise be used for innovation.”  
Id.  Avoidance of potential problems is frequently         
the best alternative:  “the numerous existing patent 
claims on genes are already affecting the use, if not 
the development, of multiplex tests in that clinicians 
are not reporting the results for patent-protected 
genes in multiplex tests for fear of inviting a law-
suit.”  Id. at 54.  Of course, not reporting the entire 
sequence revealed by WGS defeats the purpose and 
dulls the promise of combining all available genetic 
tests into one.  Moreover, WGS potentially detects 
almost all sequence variations, enabling subsequent 
reanalysis of WGS results to survey for newly identi-
fied pathological genetic variation as those discover-
ies are made.  
Turning to a direct discussion of WGS, the advisory 
committee acknowledged that, because of “the distinct 
possibility that some patent claims on genes will be 
infringed by whole-genome sequencing, these patents 
remain a concern as a potential barrier to the devel-
opment of whole-genome sequencing.”  Id. at 58.  The 
committee concluded: 
In sum, it appears that test manufacturers are 
eager to develop – and clinicians are eager to 
use – multiplex tests, rather than single-gene 
tests, to carry out genetic testing.  These tests 
would be more efficient than conducting a series 
of individual tests.  Patent claims on isolated 
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genes and association patent claims, however, 
appear to have already created a thicket of           
intellectual property rights that may prevent 
innovators from creating these multiplex tests.  
Similar concerns arise when envisioning the 
clinical application of whole-genome sequenc-
ing.  Such scenarios threaten to diminish the 
usefulness of these promising technologies and 
their application to patient care. 
Id. at 61.  Genformatic asserts that this is exactly         
the sort of inhibition of “future innovation” that con-
cerned the Court in Mayo.  132 S. Ct. at 1301, 1303.   
CONCLUSION 
The judgment of the court of appeals should be 
reversed, and the patents held invalid. 
Respectfully submitted, 
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